摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride | 157327-47-4

中文名称
——
中文别名
——
英文名称
1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride
英文别名
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bishydrochloride;1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazole hydrochloride;1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole;hydrochloride
1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride化学式
CAS
157327-47-4
化学式
C5H7N3*2ClH
mdl
——
分子量
182.053
InChiKey
XNBOTNWYTFAMAA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.43
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    40.7
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

反应信息

  • 作为反应物:
    描述:
    4-nitrophenyl N-[[5-(benzenesulfonyl)pyridin-2-yl]methyl]carbamate1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride三乙胺 作用下, 以 乙醇 为溶剂, 以23%的产率得到N-[[5-(benzenesulfonyl)-2-pyridyl]methyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-carboxamide
    参考文献:
    名称:
    [EN] PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES
    [FR] DÉRIVÉS SULFONES ET SULFOXYDES PYRIDINYLIQUES ET PYRIMIDINYLIQUES
    摘要:
    披露了某些吡啶基和嘧啶基亚砜和砜化合物,包括这些化合物的药物组合物以及使用这些化合物的治疗方法。
    公开号:
    WO2013127267A1
  • 作为产物:
    描述:
    3-((二甲基氨基)亚甲基)-4-氧代吡咯烷-1-羧酸叔丁酯一水合肼盐酸 作用下, 以 甲醇三氟乙酸乙醇 为溶剂, 反应 2.0h, 以88%的产率得到1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride
    参考文献:
    名称:
    Synthesis of the Bicyclic Secondary Amines via Dimethylaminomethylene Ketones from 3-Pyrrolidone and 4-Piperidone
    摘要:
    The reaction of N-protected 3-pyrrolidone and 4-piperidone with N,N-dimethylformamide dimethyl acetal gave the dimethylaminomethylene ketones, which reacted with several types of hydrazines, amidines, and guanidine to afford the secondary amines having fused ring system.
    DOI:
    10.3987/com-01-s(k)25
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2017216726A1
    公开(公告)日:2017-12-21
    The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    该发明涉及取代吡啶衍生物。具体而言,该发明涉及符合以下式(Iar)的化合物:(Iar)其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义;或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂,可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此,该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
  • [EN] AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS SULFONAMIDES ET AMIDES AMIDO-SPIROCYCLIQUES
    申请人:GENENTECH INC
    公开号:WO2013127269A1
    公开(公告)日:2013-09-06
    Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    提供了螺环氨基和磺胺基化合物,包括这些化合物的药物组合物,以及使用这些化合物进行治疗的方法。
  • Asymmetric Synthesis of Highly Functionalized Tetrahydropyran DPP-4 Inhibitor
    作者:Feng Xu、Michael J. Zacuto、Yoshinori Kohmura、Jon Rosen、Andrew Gibb、Mahbub Alam、Jeremy Scott、David Tschaen
    DOI:10.1021/ol502661g
    日期:2014.10.17
    A practical synthesis of a highly functionalized tetrahydropyran DPP-4 inhibitor is described. The asymmetric synthesis relies on three back-to-back Ru-catalyzed reactions. A Ru-catalyzed dynamic kinetic resolution (DKR) reduction establishes two contiguous stereogenic centers in one operation. A unique dihydropyran ring is efficiently constructed through a preferred Ru-catalyzed cycloisomerization
    描述了高度官能化的四氢吡喃DPP-4抑制剂的实用合成。不对称合成依赖于三个背对背Ru催化的反应。Ru催化的动态动力学拆分(DKR)还原可在一次操作中建立两个连续的立体生成中心。通过优选的Ru催化的环异构化可有效地构建独特的二氢吡喃环。硼氢化然后Ru催化氧化可提供所需的官能化吡喃酮核心支架。最后,立体选择性还原胺化反应和随后的酸性脱保护反应以25%的总收率提供了所需的有效DPP-4抑制剂。
  • PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES
    申请人:Bair Kenneth W
    公开号:US20150175621A1
    公开(公告)日:2015-06-25
    Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.
    本发明涉及某些吡啶基和嘧啶基亚砜和磺酰化合物、包含这些化合物的制药组合物以及使用这些化合物的治疗方法。
  • AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES
    申请人:GENENTECH, INC.
    公开号:US20160002266A1
    公开(公告)日:2016-01-07
    Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    本发明提供了含有螺环酰胺和磺酰胺化合物的药物组合物,以及使用这些化合物的治疗方法。
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-2-cyclopropyl-3-(trifluoromethyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5-isopropylaminocarbonyl-3-phenyl-1-polystyrenenethylaminocarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole 5-(6-{[(3,4-cis)-3-fluoropiperidin-4-yl]oxy}-5-methylpyrimidin-4-yl)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-2-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5,5-dimethyl-2-(6-methylpyridin-2-yl)-3-(pyridine-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 5,5-dimethyl-2-(pyridin-2-yl)-3-(pyridin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 3-bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 1-cyano-2,3,7-triazabicyclo[3.3.0]oct-2-ene 3-(aminomethyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid 1,1-dimethylethyl ester 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-1,3-dimethyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-hydroxy-2-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one